Study to investigate the efficacy and tolerability of AZD1446 in Adult ADHD patients.

Study identifier:D1950C00007

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase IIa, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-Over Study to Assess the Efficacy, Safety ,tolerability and Pharmacokinetics of Three Oral AZD1446 Dose Regimens and Placebo During 2 weeks of Treatment in Adult Non-Users and users of Nicotine Containing Products

Medical condition

Adult ADHD

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD1446,, AZD1446, qd, AZD1446, tid, Placebo

Sex

All

Actual Enrollment

79

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Nov 2009
Primary Completion Date: 01 Aug 2010
Study Completion Date: 01 Aug 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria